DayTwo Secures $12.0M in Series A Financing
Summary
DayTwo, a Tel Aviv, Israel and San Francisco, California-based developer of a microbiome-health management platform, completed a $12.0m Series A round of financing.Led by Chief Executive Officer Lihi Segal, DayTwo has developed a method to accurately predict an individual’s glycemic response to specific foods and food combinations using an individual’s microbiome and other clinical factors.Day Two can bring a personalized diet and nutrition plan to individuals, based on accurately predicting their own glycemic response.The personalized nutrition offering is based on the original research led by Professors Eran Segal and Eran Elinav from the Weizmann Institute of Science in Israel, and published in the scientific journal Cell.For clinicians and health practitioners, DayTwo brings actionable insights for diet and nutrition to the care plans and meal plans of their patients and provides an additional path for clinicians and their patients to stay connected.